Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord mesenchymal stem cells (hUC-MSCs) developed by Southeast University are an allogeneic cell therapy being evaluated for the treatment of acute respiratory distress syndrome (ARDS). These multipotent stem cells possess potent immunomodulatory and anti-inflammatory properties, which are hypothesized to mitigate the 'cytokine storm' and lung tissue injury characteristic of ARDS. Upon intravenous administration, these cells tend to sequester in the pulmonary microvasculature, where they can secrete paracrine factors that promote alveolar epithelial and endothelial repair, enhance alveolar fluid clearance, and shift the immune response from a pro-inflammatory to an anti-inflammatory state.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (Southeast University).